


CLAIMS

1. A group B adenovirus comprising a sequence of formula **(I)**:



wherein:

B_1 is a bond or comprises: E1A, E1B or E1A-E1B;

B_A comprises-E2B-L1-L2-L3-E2A-L4;

B_2 is a bond or comprises: E3;

B_X is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both;

B_B comprises L5;

B_Y comprises a sequence -G1-G2_n-G3_m-G4_p-G5_q,

wherein: **G1** is a first transgene; **G2** is a second transgene; **G3** is a third transgene; **G4** is a fourth transgene; **G5** is a fifth transgene,

B_3 is a bond or comprises: E4;

n is 0 or 1; **m** is 0 or 1; **p** is 0 or 1; **q** is 1;

B_3 is a bond or comprises: E4;

wherein:

IL-15 is encoded as a transgene in position G5,

characterised in that B_Y also encodes a polypeptide comprising the sushi domain of IL-15R alpha, and does not comprise a transmembrane or GPI anchor such that it is not membrane anchored when expressed.

2. A group B adenovirus according to claim 1, wherein the polypeptide encoding the sushi domain does not comprise a transmembrane domain or GPI anchor.
3. A group B adenovirus according to claim 1 or 2, wherein p is 1 and the polypeptide comprising the IL-15R alpha sushi domain is encoded in G4.
4. A group B adenovirus according to any one of claims 1 to 3, wherein the leader sequence as employed for IL-15 is the non-native sequence selected independently from Ig, CD33 or IL-2 leader sequence.
5. A group B adenovirus according to any one of claims 1 to 4, wherein the virus also encodes IL-12.
6. A group B adenovirus according to claim 5, wherein IL-12 has a sequence shown in SEQ ID NO: 115.
7. A group B adenovirus according to claim 5 or 6 wherein IL-12 is encoded in G1 or G2.
8. A group B adenovirus according to any one of claims 1 to 8, where at least one further cytokine is encoded in B_Y .
9. A group B adenovirus according to any one of claims 1 to 9, wherein B_Y encodes at least one chemokine.
10. A group B adenovirus according to claim 10, wherein the chemokine is selected from CXCL9, CCL19 and CCL21.
11. A group B adenovirus according to claim 10 or 11 wherein the chemokine is encoded in G1, G2 and/or G3.
12. A group B adenovirus according to any one of claims 1 to 11, wherein m is 0.

13. A group B adenovirus according to any one of claims 1 to 12, wherein the one or more transgenes (such as all transgenes) in BY are under the control of the major later promoter.
14. A group B adenovirus according to claim 1 wherein the virus comprises a DNA sequence encoding a protein sequence selected from SEQ ID NO: 175 to 189.
15. A composition comprising a group B adenovirus according to any one of claims 1 to 14 and a pharmaceutically acceptable excipient, diluent or carrier.
16. A group B adenovirus according to any one of claims 1 to 14 or a composition according to claim 15 for use in therapy.
17. Use of a group B adenovirus according to any one of claims 1 to 14 or a composition according to claim 15 in the manufacture of a medicament for treating cancer.
18. A combination therapy comprising a virus according to any one of one of claims 1 to 14 and a cellular therapy for use in therapy.